Skip to content

Etanercept

Enbrel (etanercept) is a protein pharmaceutical. Etanercept was first approved as Enbrel on 1998-11-02. It is used to treat ankylosing spondylitis, juvenile arthritis, psoriatic arthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat ankylosing spondylitis, juvenile arthritis, psoriasis, psoriatic arthritis, and rheumatoid arthritis amongst others. The pharmaceutical is active against tumor necrosis factor. In addition, it is known to target lymphotoxin-alpha.
Trade Name Enbrel
Common Name Etanercept
ChEMBL ID CHEMBL1201572
Indication ankylosing spondylitis, juvenile arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, spondylarthropathies
Drug Class Receptor molecules, native or modified: tumor necrosis factor receptors
Etanercept
Get full access now